News >

Trastuzumab Biosimilars Demonstrate Equivalence Across Breast Cancer Settings

Caroline Seymour
Published: Tuesday, Oct 23, 2018

Dr Hope Rugo

Hope S. Rugo, MD
Early-stage and metastatic breast cancer are appropriate settings to test the equivalence of biosimilars and originator products, according to a systematic literature review presented at the 2018 ESMO Congress.

during the 2018 ESMO Congress, Rugo, professor of medicine and director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed this analysis of trastuzumab biosimilars in breast cancer.

OncLive: Could you provide an overview of the comparative review of trastuzumab biosimilars in breast cancer?

Rugo: We had a poster looking at the different biosimilar trials. We were interested in looking at whether or not there was any evidence that one setting was preferable to study biosimilarity. We looked specifically at the biosimilar trastuzumab trials compared with the originator. There has been some discussion that you may have better response if you look at the biosimilar trastuzumab agents in the neoadjuvant setting versus the first-line metastatic setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication
x